Literature DB >> 17135770

Prevalence and severity of anaemia in patients with type 2 diabetic nephropathy and different degrees of chronic renal insufficiency.

Maurizio Li Vecchi1, Giorgio Fuiano, Marino Francesco, Domenico Mancuso, Teresa Faga, Andrea Sponton, Rossana Provenzano, Michele Andreucci, Carmela Tozzo.   

Abstract

BACKGROUND/AIM: Type 2 diabetes mellitus is the single most common cause of chronic kidney disease (CKD); however its real impact on renal anaemia has not been established. The aim of this study was to evaluate whether onset, severity, and prevalence of anaemia during the course of CKD is different between type 2 diabetic and non-diabetic patients.
METHODS: We enrolled 281 patients with: (1) type 2 diabetes and no CKD (n = 75); (2) type 2 diabetes plus CKD (n = 106), and (3) CKD without type 2 diabetes (n = 100). According to K/DOQI guidelines, the patients with renal insufficiency (i.e., those with a glomerular filtration rate <60 ml/min) were subgrouped into three tertiles of CKD: (1) stage 3 (creatinine clearance 60-30 ml/min); (2) stage 4 (creatinine clearance 29-15 ml/min), and (3) stage 5 (creatinine clearance <15 ml/min).
RESULTS: Anaemia was observed in 16% of the diabetic patients without CKD; it was more frequent in the diabetic patients with CKD than in the non-diabetic patients with CKD (61.7 vs. 52%, p < 0.05). The comparison among the tertiles showed that the prevalence of anaemia was significantly higher only in diabetic CKD patients of stages 4 and 5. The prevalence was higher in females independently of type 2 diabetes mellitus. In diabetics with a normal renal function, the haemoglobin levels were higher than in diabetics and non-diabetics with CKD, but the diabetics showed lower levels of haemoglobin than non-diabetics at stage 3 and stage 4 of CKD.
CONCLUSIONS: Diabetic patients with CKD of stages 4 and 5 have a higher prevalence of anaemia than non-diabetic patients with comparable glomerular filtration rate. A higher awareness of this risk will allow earlier diagnosis and treatment. Copyright 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17135770     DOI: 10.1159/000097600

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  9 in total

1.  New-onset anemia and associated risk of ESKD and death in non-dialysis CKD patients: a multicohort observational study.

Authors:  Roberto Minutolo; Michele Provenzano; Paolo Chiodini; Silvio Borrelli; Carlo Garofalo; Michele Andreucci; Maria Elena Liberti; Vincenzo Bellizzi; Giuseppe Conte; Luca De Nicola
Journal:  Clin Kidney J       Date:  2022-01-12

2.  Endothelial activation markers in anemic non-dialysis chronic kidney disease patients.

Authors:  Tejas V Patel; Bharati V Mittal; Sai Ram Keithi-Reddy; Jeremy S Duffield; Ajay K Singh
Journal:  Nephron Clin Pract       Date:  2008-10-31

3.  Parathyroid hormone may be an early predictor of low serum hemoglobin concentration in patients with not advanced stages of chronic kidney disease.

Authors:  Domenico Russo; Luigi Morrone; Biagio Di Iorio; Michele Andreucci; Maria Grazia De Gregorio; Carmela Errichiello; Luigi Russo; Francesco Locatelli
Journal:  J Nephrol       Date:  2014-08-12       Impact factor: 3.902

4.  Anaemia among primary care patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD): a multicentred cross-sectional study.

Authors:  Iliza Idris; Hizlinda Tohid; Noor Azimah Muhammad; Mohd Radzniwan A Rashid; Azainorsuzila Mohd Ahad; Norsiah Ali; Naemah Sharifuddin; Junita Harizon Aris
Journal:  BMJ Open       Date:  2018-12-22       Impact factor: 2.692

5.  Identification of circular RNAs and functional competing endogenous RNA networks in human proximal tubular epithelial cells treated with sodium-glucose cotransporter 2 inhibitor dapagliflozin in diabetic kidney disease.

Authors:  Yi Song; Feng Guo; Yifan Liu; Fengjuan Huang; Xunjie Fan; Lin Zhao; Guijun Qin
Journal:  Bioengineered       Date:  2022-02       Impact factor: 6.832

Review 6.  Sodium-Glucose Co-transporter-2 Inhibitors and Nephroprotection in Diabetic Patients: More Than a Challenge.

Authors:  Michele Provenzano; Maria Chiara Pelle; Isabella Zaffina; Bruno Tassone; Roberta Pujia; Marco Ricchio; Raffaele Serra; Angela Sciacqua; Ashour Michael; Michele Andreucci; Franco Arturi
Journal:  Front Med (Lausanne)       Date:  2021-06-04

7.  Magnitude and factors associated with anemia among diabetic patients in Ethiopia: A systematic review and meta-analysis.

Authors:  Daniel Atlaw; Zerihun Tariku
Journal:  SAGE Open Med       Date:  2021-07-09

Review 8.  Clinical predictive factors in diabetic kidney disease progression.

Authors:  Nicholas J Radcliffe; Jas-Mine Seah; Michele Clarke; Richard J MacIsaac; George Jerums; Elif I Ekinci
Journal:  J Diabetes Investig       Date:  2016-06-08       Impact factor: 4.232

Review 9.  Role of a Dual Glucose-Dependent Insulinotropic Peptide (GIP)/Glucagon-like Peptide-1 Receptor Agonist (Twincretin) in Glycemic Control: From Pathophysiology to Treatment.

Authors:  Maria Chiara Pelle; Michele Provenzano; Isabella Zaffina; Roberta Pujia; Federica Giofrè; Stefania Lucà; Michele Andreucci; Angela Sciacqua; Franco Arturi
Journal:  Life (Basel)       Date:  2021-12-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.